(Reuters) – The European health regulator’s advisory panel issued a negative opinion for PTC Therapeutics’ drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the company said on Thursday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
Comments